Explore / Stock comparison 2 of 3 daily views used · 1 remaining. Refreshes and chart changes do not use another view.
Price Valuation Financials
Daily close · 2026-10-12 Price return Closing price
Quarterly Yearly
Price return Both stocks start at 0% on the first shared trading day.
Price return: BOLT and GNTA Historical recorded observations on the same scale. Missing metrics leave gaps. -105% -74% -43% -12% 20% 2021 2022 2023 2024 2025 2026
Use left and right arrow keys to inspect historical line observations. Financial bars can be focused individually.
Split-adjusted closing prices. Dividends are excluded. Explore stocks within your daily allowance.
Enable JavaScript to change metrics, ranges and fiscal cadence. The initial chart and financial table remain available.
Business overlap Businesses Fundamentals Methodology Similarity 100.0%
5 shared / 5 total tags How similar are their businesses? The score compares business activities in annual filings released in 2025. Core activities receive four times the weight of material activities. Industries that fewer companies share carry more weight.
Biotechnology Healthcare Immunotherapy Oncology Pharmaceuticals
How we measure overlap ↗ The businesses behind the score
Industry overlap Filing-derived business activity overlap Counts of retained positive business classifications. Circle sizes do not encode the counts or the weighted similarity score. BOLT only 0 Shared 5 GNTA only 0 BOLT only · 0 No activities in this group.
Shared activities · 5 BiotechnologyBOLT: Core · GNTA: Core ↗ Filing evidence HealthcareBOLT: Core · GNTA: Core ↗ Filing evidence ImmunotherapyBOLT: Core · GNTA: Core ↗ Filing evidence OncologyBOLT: Core · GNTA: Core ↗ Filing evidence PharmaceuticalsBOLT: Core · GNTA: Core ↗ Filing evidence GNTA only · 0 No activities in this group.
Positive activities from the two selected annual filings. Up to six activities per group are shown here; every activity remains in the complete table. These are classification sets, not revenue shares. The weighted similarity score also accounts for exposure and how common each activity is. Show business activity table · 5 rows, 3 columns All 5 Shared 5 Different 0
Core activities receive full weight; material activities receive one quarter. Select a tag to read the filing evidence.
BOLT Core Annual filing released 2025-03-24 · GPT 6 Luna
We are a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. Our pipeline candidates are built on our deep expertise in myeloid biology and cancer drug development. Our product candidates use pattern recognition receptors in the innate immune system to help the body recognize tumor cells for a productive anti-cancer response. Our proprietary Boltbody™ ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. We believe this approach has the potential to create products that work with a patient’s own immune system, resulting in anti-cancer efficacy with good tolerability. BDC-3042, our dectin-2 agonist antibody program, leverages our myeloid biology expertise to target tumor associated macrophages (TAMs). We have completed enrollment of our dose escalation study without any dose-limiting toxicities and will be reporting results from the Phase 1 study in the second quarter of 2025.
Our Pipeline Read the annual filing ↗ GNTA Core Annual filing released 2025-03-28 · GPT 6 Luna
We
are a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of
solid tumors. We have developed a novel biologic platform that involves the ex-vivo gene transfer of a therapeutic candidate into
autologous hematopoietic stem/progenitor cells (“HSPCs”) to deliver immunomodulatory molecules directly to the tumor by infiltrating
monocytes/macrophages (Tie2 Expressing Monocytes – “TEMs”). Our technology is designed to turn TEMs, which normally
have an affinity for and travel to tumors, into a “Trojan Horse” to counteract cancer progression and to prevent tumor relapse.
Our technology is not target dependent, and therefore we believe it can be used as a treatment for a broad variety of cancers.
63 Genenta
is an early-stage company developing first-in-class cell and gene therapies to address unmet medical needs in cancerous solid tumors.
The Company is initially developing its clinical leading product, Temferon™, to treat glioblastoma multiforme (“GBM”),
a solid tumor affecting the brain. The Company intends to continue its clinical trials in Italy and eventually start a clinical trial
in Europe and the U.S. to study Temferon™ in other cancers. In June 2023, the Company’s Board of Directors selected metastatic
Renal Cell Cancer (“mRCC”) as the second solid tumor indication for Temferon. The Company is currently enrolling patients
for a Phase 1 trial in mRCC. The Company has recently completed its Phase 1 trial in GBM and its Phase 2a trial in GBM is ongoing. Read the annual filing ↗ BOLT Core Annual filing released 2025-03-24 · GPT 6 Luna
We are a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. Our pipeline candidates are built on our deep expertise in myeloid biology and cancer drug development. Our product candidates use pattern recognition receptors in the innate immune system to help the body recognize tumor cells for a productive anti-cancer response. Our proprietary Boltbody™ ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. We believe this approach has the potential to create products that work with a patient’s own immune system, resulting in anti-cancer efficacy with good tolerability. BDC-3042, our dectin-2 agonist antibody program, leverages our myeloid biology expertise to target tumor associated macrophages (TAMs). We have completed enrollment of our dose escalation study without any dose-limiting toxicities and will be reporting results from the Phase 1 study in the second quarter of 2025.
Our Pipeline Read the annual filing ↗ GNTA Core Annual filing released 2025-03-28 · GPT 6 Luna
We
are a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of
solid tumors. We have developed a novel biologic platform that involves the ex-vivo gene transfer of a therapeutic candidate into
autologous hematopoietic stem/progenitor cells (“HSPCs”) to deliver immunomodulatory molecules directly to the tumor by infiltrating
monocytes/macrophages (Tie2 Expressing Monocytes – “TEMs”). Our technology is designed to turn TEMs, which normally
have an affinity for and travel to tumors, into a “Trojan Horse” to counteract cancer progression and to prevent tumor relapse.
Our technology is not target dependent, and therefore we believe it can be used as a treatment for a broad variety of cancers.
63 Operating
segments are identified as components of an enterprise for which separate discrete financial information is available for evaluation
by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company and its
chief operating decision-maker view the Company’s operations and manages its business in one operating segment, which is the research
and development in the pharmaceutical sector with a focus on developing novel therapeutics to treat cancer.
Tax
credit on investments in research and development Read the annual filing ↗ BOLT Core Annual filing released 2025-03-24 · GPT 6 Luna
We are a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. Our pipeline candidates are built on our deep expertise in myeloid biology and cancer drug development. Our product candidates use pattern recognition receptors in the innate immune system to help the body recognize tumor cells for a productive anti-cancer response. Our proprietary Boltbody™ ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. We believe this approach has the potential to create products that work with a patient’s own immune system, resulting in anti-cancer efficacy with good tolerability. BDC-3042 is an agonist antibody targeting dectin-2, an innate immune receptor found on the surface of macrophages. dectin-2 is selectively expressed in TAMs across a broad range of tumor types, including non-small cell lung, head and neck, ovarian, triple-negative breast cancer, and melanoma, among others. Most of these TAMs seem to be immunosuppressive, and agonism of dectin-2 converts them to an immunostimulatory phenotype, inducing pro-inflammatory cytokine production, enhanced phagocytosis, and antigen processing and presentation. A dectin-2 agonist antibody has the potential to convert these immunosuppressive TAMs into tumor-destructive macrophages that elicit productive anti-tumor immune responses. Anti-PD-1 therapies have been shown to upregulate the expression of dectin-2 in tumors, which provides an interesting rationale for exploring this combination. Read the annual filing ↗ GNTA Core Annual filing released 2025-03-28 · GPT 6 Luna
Our
lead product candidate, Temferon, consists of genetically modified HSPCs which use our platform to deliver interferon-alpha (“IFN-α”),
within the tumor microenvironment via TEMs (HSPCs differentiated myeloid progeny). The IFN-α reduces angiogenesis, counteracts
tumor cells proliferation and breaks the established immune-tolerance, enabling the immune system to recognize the tumor. IFN-α
is a proven and known immunomodulatory molecule, or cytokine, that has limited clinical use due to the systemic toxicity associated with
its intravenous administration. Our technology is designed to protect the HSPCs from IFN-α mediated activation that could negatively
impact their repopulation capacity as reported in some studies of repeated systemic administration of high doses of IFN-α. The
investigational treatment involves the use of autologous CD34+-enriched hematopoietic progenitor cells genetically modified with a lentiviral
vector encoding human interferon-α2. This therapy is specifically targeted at adult patients aged 18 to 70 years with GBM characterized
by an unmethylated O-6-methylguanine-DNA methyltransferase (MGMT) gene promoter, a subgroup known for poorer response to standard therapies.
We believe this trial represents an innovative strategy for modulating the tumor microenvironment and enhancing anti-tumor immunity in
GBM patients. Read the annual filing ↗ BOLT Core Annual filing released 2025-03-24 · GPT 6 Luna
We are a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. Our pipeline candidates are built on our deep expertise in myeloid biology and cancer drug development. Our product candidates use pattern recognition receptors in the innate immune system to help the body recognize tumor cells for a productive anti-cancer response. Our proprietary Boltbody™ ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. We believe this approach has the potential to create products that work with a patient’s own immune system, resulting in anti-cancer efficacy with good tolerability. BDC-3042, our dectin-2 agonist antibody program, leverages our myeloid biology expertise to target tumor associated macrophages (TAMs). We have completed enrollment of our dose escalation study without any dose-limiting toxicities and will be reporting results from the Phase 1 study in the second quarter of 2025.
Our Pipeline Read the annual filing ↗ GNTA Core Annual filing released 2025-03-28 · GPT 6 Luna
In preclinical mouse cancer models treated with Temferon both direct (anti-angiogenic,
pro-apoptotic) and indirect (immune response) effects were observed.
We
are currently developing Temferon for the treatment of glioblastoma multiforme (“GBM”) in patients who have an unmethylated
MGMT gene promoter (“uMGMT-GBM”). GBM is the most common malignant primary brain tumor, accounting for more than half of
all central nervous system cancers. Patients suffering from GBM have limited, non-curative treatment options. Although these treatments
may improve survival, the prognosis for GBM patients remains poor, with a median overall survival (“mOS”) of approximately
13 to 15 months and only 5.5% of patients estimated to be alive five (5) years after diagnosis. With no curative treatments available
and such poor prognosis for patients, there remains a large, unmet medical need. We
are currently conducting two Phase 1/2a studies in Italy, to primarily evaluate the safety and tolerability of Temferon. We have completed
the Phase 1 portion of the TEM-GBM Phase 1/2a study, which administered escalating doses of Temferon to GBM patients with an unmethylated
MGMT promoter following radiotherapy. The study generated encouraging preliminary evidence of potential disease modification, including
an increase in the percentage of long-term survivors (LTS) at two years compared to data reported in literature and from a registry which
included matched patient population undergoing standard of care. Read the annual filing ↗ BOLT Core Annual filing released 2025-03-24 · GPT 6 Luna
We are a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. Our pipeline candidates are built on our deep expertise in myeloid biology and cancer drug development. Our product candidates use pattern recognition receptors in the innate immune system to help the body recognize tumor cells for a productive anti-cancer response. Our proprietary Boltbody™ ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. We believe this approach has the potential to create products that work with a patient’s own immune system, resulting in anti-cancer efficacy with good tolerability. BDC-3042, our dectin-2 agonist antibody program, leverages our myeloid biology expertise to target tumor associated macrophages (TAMs). We have completed enrollment of our dose escalation study without any dose-limiting toxicities and will be reporting results from the Phase 1 study in the second quarter of 2025.
Our Pipeline Read the annual filing ↗ GNTA Core Annual filing released 2025-03-28 · GPT 6 Luna
Our
lead product candidate, Temferon, was developed using our proprietary platform and carries the interferon-alpha (“IFN-α”)
payload. IFN-α is a well-known therapeutic that was previously administered intravenously for treatment of various cancers, but
it is currently rarely used because of its systemic toxicity. The Temferon-modified TEMs express the transgene payload, IFN-α,
in the tumor microenvironment, thereby reprogramming the Tumor Micro Environment (“TME”) which disrupts tumor induced immune-tolerance
in blocks. Consequently, the immune system has been observed to recognize the tumor, respond, and inhibit tumor growth. Because Temferon
is designed to deliver the IFN-α payload directly into the tumor, we believe it will demonstrate clinical activity without the
side effect profile of systemic delivery of IFN-α. In preclinical mouse cancer models treated with Temferon both direct (anti-angiogenic,
pro-apoptotic) and indirect (immune response) effects were observed.
We
are currently developing Temferon for the treatment of glioblastoma multiforme (“GBM”) in patients who have an unmethylated
MGMT gene promoter (“uMGMT-GBM”). GBM is the most common malignant primary brain tumor, accounting for more than half of
all central nervous system cancers. Patients suffering from GBM have limited, non-curative treatment options. Although these treatments
may improve survival, the prognosis for GBM patients remains poor, with a median overall survival (“mOS”) of approximately
13 to 15 months and only 5.5% of patients estimated to be alive five (5) years after diagnosis. With no curative treatments available
and such poor prognosis for patients, there remains a large, unmet medical need. Read the annual filing ↗ What each company does Compare the businesses BS
Bolt Biotherapeutics, Inc. Common Stock BOLT · XNAS Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company dBDC-3042, develops dan agonist antibody targeting Dectin-2 for range of tumors, such as head and neck, non-small cell lung, ovarian, triple-negative breast, and other cancer; and BDC-4182, an next-generation boltbody technology platform that targets claudin 18.2, which is overexpressed in gastric/gastroesophageal junction cancer, pancreatic cancer, and other tumor types. The company has collaboration agreements with Toray Industries, Genmab A/S, Innovent Biologics, Inc.; and license agreement with Stanford University. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood City, California.
Open BOLT dashboard ↗ GS
Genenta Science S.p.A. American Depositary Shares GNTA · XNAS Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. The company is developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma. In addition, it develops biologic platform to deliver immunomodulatory molecules directly to the tumor by infiltrating monocytes/macrophages. The company was incorporated in 2014 and is headquartered in Milan, Italy.
Open GNTA dashboard ↗ Show fundamentals table · 11 rows, 3 columns USD values from stored observations. Fiscal period endings and availability dates may differ.
BOLT period ended 2025-12-31 · available 2026-03-12 · SEC filing ↗ GNTA period ended 2025-12-31 · available 2026-03-31 · SEC filing ↗ Behind the comparison Sources and methodology Price return uses split-adjusted daily closes and excludes dividends. Both stocks start on the first shared trading day within the selected window. Unavailable metrics leave gaps.
Financials use SEC canonical statements available by the displayed cutoff, retaining each company's fiscal period end. Annual and quarterly amounts are shown separately. P/E is unavailable when earnings do not support a positive ratio.
Business overlap uses industry tags from annual filings released in 2025. Each core activity receives full weight; each material activity receives one quarter of that weight. Rarer industries carry more weight. We sum the smaller exposure for each shared activity and divide it by the sum of the larger exposure for every activity in either company. This measures business overlap, rather than price correlation or expected returns.
Related comparisons require a shared specific core activity and at least 20% overlap. Broad categories alone do not establish a close peer relationship. Identical classifications can score 100% even when companies sell different products. We select up to ten leading peers per issuer for discovery, combine both directions, and require current common shares, public company profiles and stored price observations. Arbitrary stock pairs remain available.
Statements available through 2026-10-14. Industry snapshot: 2025-12-31 · 5,721 classified issuers.